A New Way to
Detect Cancer
DELFI at ATS 2023
As a next-generation liquid biopsy company, DELFI Diagnostics is developing a rich pipeline of products designed to save lives by detecting cancer at its earliest stages. Our whole-genome fragmentomics platform is capable of supporting a broad range of high-performing applications to address major unmet medical needs in cancer.
Come see our presentations at ATS or stop by Booth 1139 to learn more about DELFI and our rigorous, sustainable approach to delivering new, better solutions to patients, providers, and health systems.
ORAL PRESENTATIONS
Improved Lung Cancer Detection in Setting of Underutilized CT Screening: Combination of a Lung Cancer Biomarker With Clinical Risk Assessment
Presented by Gerard A. Silvestri, MD, MS
Session Title: Advances in Biomarkers Across the Lung
Cancer Continuum
Session Date/Time: 5/23/2023 2:15 PM – 2:27 PM ET
Room: Walter E. Washington Convention Center, Room
202 B (Level 2)
Prospective Evaluation of cfDNA Fragmentomes for Lung Cancer Detection
Presented by Peter Mazzone, MD, MPH
Session Title: Advances in Biomarkers Across the Lung
Cancer Continuum
Session Date/Time: 5/23/2023 2:39 PM – 2:51 PM ET
Room: Walter E. Washington Convention Center, Room
202 B (Level 2)
ADDITIONAL DELFI PUBLICATIONS
Detection and characterization of lung cancer using cell-free DNA fragmentomes
Mathios, D., Johansen, J.S., Cristiano, S. et al. Nat Commun. 12, 5060 (2021).
Genome-wide cell-free DNA fragmentation in patients with cancer
Cristiano S, Leal A, Phallen J, et al. Nature. 570(7761):385-389 (2019)
Cell-free DNA fragmentomes in the diagnostic evaluation of patients with symptoms suggestive of lung cancer
Leal, A., Mathios, D., Jakubowski, D., et al Chest. 10.1016 – 2023.04.033 (2023)